Clinical-stage biopharmaceutical company developing therapies for metabolic and liver disorders.
89bio, Inc., headquartered in San Francisco, California, is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies targeting liver and cardio-metabolic diseases. Established in 2018, the company is dedicated to addressing significant unmet medical needs through its robust pipeline of therapeutic candidates.
At the forefront of 89bio's portfolio is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) designed to treat nonalcoholic steatohepatitis (NASH). This lead product candidate also holds promise for the treatment of severe hypertriglyceridemia, reflecting 89bio's commitment to advancing versatile treatments for complex metabolic disorders.
89bio distinguishes itself through a strategic focus on precision medicine and therapeutic innovation. By leveraging advanced scientific insights and cutting-edge technologies, the company aims to develop transformative therapies that improve patient outcomes and quality of life across global populations.
Driven by a mission to make a meaningful impact in liver and cardio-metabolic diseases, 89bio collaborates with leading researchers and healthcare providers to accelerate the development of its pipeline. With a rigorous approach to clinical development and regulatory approval, 89bio is poised to emerge as a leader in the biopharmaceutical industry, delivering novel treatments that address critical medical challenges.